BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Original Article
Year : 2026  |  Volume : 17  |  Issue : 4  |  Page : 8836-8841 Full Version
Immunohistochemical expression of l1cam in endometrial carcinoma and its association with grade and stage of tumour-a cross sectional study in patients from a tertiary health care centre in south kerala
Int J Biol Med Res. 2026; 17(4): 8836-8841  |  DOI: 10.65048/ijbmr.2026.17.4.8836.1098
¹Dr.Renu K Regi*, ²Dr.Meeta Thomas
¹,²Department of Pathology, Pushpagiri Institute of Medical Science and Research, Centre, Thiruvalla, Kerala, India
Correspondence Address :
Dr. Renu K Regi,
Department of Pathology,
Pushpagiri Institute of Medical Science and Research Centre,
Thiruvalla, Kerala, India E-mail: renuregi4@gmail.com
Received: May 8, 2026 Accepted: August 17, 2026 Published: October 3, 2026

Abstract
Introduction: Endometrial carcinoma (EC) is one among the most common gynecological malignancies worldwide, with rising incidence and significant disease-related morbidity. Although conventional prognostic factors such as tumor grade, FIGO stage, and LVSI are widely used, they do not fully explain the biological heterogeneity and variable clinical outcomes observed among patients. L1CAM, a transmembrane glycoprotein mediating in cell migration and epithelial–mesenchymal transition, has emerged as a potential biomarker associated with tumor aggressiveness and poor prognosis in endometrial carcinoma. However, its clinicopathological significance requires further evaluation, particularly in relation to tumor grade, stage, and lymphovascular invasion. Aim: To estimate the frequency of L1CAM expression in endometrial carcinoma and to evaluate its association with clinicopathological parameters including histological type, tumour grade, tumor stage, myometrial invasion, lymphovascular invasion, and lymph node involvement. Methodology: This was a hospital-based observational study conducted on histopathologically confirmed cases of endometrial carcinoma. Formalin-fixed, paraffin-embedded tissue sections were analyzed using immunohistochemistry for L1CAM expression. Tumors were classified according to WHO histological criteria and staged as per the FIGO staging system. L1CAM positivity was defined based on membranous staining in tumor cells exceeding the established cutoff. Clinicopathological parameters including age, histological subtype, tumor grade, FIGO stage, and presence of lymphovascular invasion were recorded. Statistical analysis was conducted to assess associations between L1CAM expression and clinicopathological variables, with p-value <0.05 considered statistically significant.
Result: L1CAM expression was observed in a subset of endometrial carcinoma cases and was significantly associated with higher tumor grade and advanced FIGO stage. A strong correlation was noted between L1CAM positivity and the presence of lymphovascular space invasion. Tumors expressing L1CAM were more frequently high-grade, non-endometrioid, and demonstrated aggressive pathological features. L1CAM expression showed a statistically significant association with adverse prognostic indicators, suggesting its role as a marker of tumor aggressiveness. Conclusion: L1CAM expression is significantly associated with higher tumor grade, advanced stage, and lymphovascular invasion in endometrial carcinoma. Its expression identifies a subgroup of tumors with aggressive biological behavior and poorer prognostic features. Incorporation of L1CAM immunohistochemistry into routine histopathological evaluation may improve risk stratification and to identify patients who are likely to benefit from closer surveillance and aggressive adjuvant therapy. L1CAM also holds promise as a potential therapeutic target in high-risk endometrial carcinoma.
Keywords
Endometrial carcinoma, L1CAM, Lymphovascular space invasion, Tumor grade, FIGO staging

References

[1] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022;399(10333):1412–28. 
[2] Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. JNCI J Natl Cancer Inst. 2018;110(4):354–61. 
[3] Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers. 2021;13(11):2623. 
[4] Duncan BW, Murphy KE, Maness PF. Molecular mechanisms of L1 and NCAM adhesion molecules in synaptic pruning, plasticity, and stabilization. Front Cell Dev Biol. 2021;9:625340. 
[5] Stoyanova II, Lutz D. Functional diversity of neuronal cell adhesion and recognition molecule L1CAM through proteolytic cleavage. Cells. 2022;11(19):3085. 
[6] Sytnyk V, Leshchyns’ka I, Schachner M. Neural cell adhesion molecules of the immunoglobulin superfamily regulate synapse formation, maintenance, and function. Trends Neurosci. 2017;40(5):295–308. 
[7] Kim J, Kim SI, Kim NR, Kim H, Kim HS, Chung HH, et al. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer. Gynecol Oncol. 2023;174:231–8. 
[8] Giannini A, D’Oria O, Corrado G, Bruno V, Sperduti I, Bogani G, et al. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024;309(3):789–99. 
[9] Kommoss F, Kommoss F, Grevenkamp F, Bunz AK, Taran FA, Fend F, et al. L1CAM: amending the “low-risk” category in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143:255–62. 
[10] Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, et al. Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on The Cancer Genome Atlas (TCGA)-based molecular subgroup. Am J Surg Pathol. 2017;41(2):245–52. 
[11] Arciuolo D, Travaglino A, Santoro A, Scaglione G, D’Alessandris N, Valente M, et al. L1CAM expression in Microcystic, Elongated, and fragmented (MELF) glands predicts Lymph Node involvement in endometrial Carcinoma. Cancers. 2022;14(15):3635. 
[12] Duraiyan J, Govindarajan R, Kaliyappan K, Palanisamy M. Applications of immunohistochemistry. J Pharm Bioallied Sci [Internet]. 2012 Aug [cited 2024 Aug 29];4(Suppl 2):S307. Available from: https://journals.lww.com/jpbs/fulltext/2012/04002/applications_of_immunohistochemistry.47.aspx
[13] Dabbs DJ. Diagnostic immunohistochemistry: theranostic and genomic applications. Elsevier Health Sciences; 2010. 
[14] Angiolini F, Cavallaro U. The pleiotropic role of L1CAM in tumor vasculature. Int J Mol Sci. 2017;18(2):254. 
[15] Wu Z, Wu Y, Liu Z, Song Y, Ge L, Du T, et al. L1CAM deployed perivascular tumor niche promotes vessel wall invasion of tumor thrombus and metastasis of renal cell carcinoma. Cell Death Discov. 2023;9(1):112. 
[16] Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Abdel Azim S, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013;105(15):1142–50. 
[17] Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedermair A, Rössler J, et al. Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. Oncotarget. 2016;7(26):40221. 
[18] Dellinger TH, Smith DD, Ouyang C, Warden CD, Williams JC, Han ES. L1CAM is an independent predictor of poor survival in endometrial cancer—an analysis of The Cancer Genome Atlas (TCGA). Gynecol Oncol. 2016;141(2):336–40. 
[19] Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol. 2016;29(2):174–81. 
[20] Van Der Putten LJ, Visser N, Van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016;115(6):716–24. 
[21] Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, et al. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. BMC Cancer. 2016;16:1–8. 
[22] Geels YP, Pijnenborg JM, Gordon BB, Fogel M, Altevogt P, Masadah R, et al. L1CAM expression is related to non-endometrioid histology, and prognostic for poor outcome in endometrioid endometrial carcinoma. Pathol Oncol Res. 2016;22:863–8. 
[23] Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017;3(4):279–93. 
[24] Tangen IL, Kopperud RK, Visser N, Staff AC, Tingulstad S, Marcickiewicz J, et al. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. Br J Cancer. 2017;117(6):840–7. 
[25] Kommoss S, Hartkopf AD, Krämer B, Bunz AK, Grevenkamp F, Kommoss F, et al. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143:2183–8. 
[26] Soovares P, Pasanen A, Bützow R, Lassus H. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. Gynecol Oncol. 2017;146(3):615–22. 
[27] Azim SA, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C. L1CAM and HER2 expression in early endometrioid uterine cancer. Int J Gynecol Pathol. 2017;36(4):356–63. 
[28] Pasanen A, Loukovaara M, Tuomi T, Butzow R. Preoperative risk stratification of endometrial carcinoma: L1CAM as a biomarker. Int J Gynecol Cancer. 2017;27(7):1318–24. 
[29] Versluis M, Plat A, de Bruyn M, Matias-Guiu X, Trovic J, Krakstad C, et al. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial–mesenchymal transition. Virchows Arch. 2018;473:591–8. 
[30] Van Der Putten LJ, Visser NC, Van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. Added Value of Estrogen Receptor, ProgesteroneReceptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. Int J Gynecol Cancer. 2018;28(3):514–23. 
[31] Geels YP, van der Putten LJ, van Tilborg AA, Nienhaus BE, van den Berg-van SH, Snijders MP, et al. Immunohistochemical profiles of endometrioid endometrial carcinomas with and without metastatic disease. Appl Immunohistochem Mol Morphol. 2018;26(3):173–9. 
[32] Salem AM, Mahdy ER. Sex-determining region y (SRY)-Box2 (SOX2) & L1-cell adhesion molecule (L1CAM) expressions in endometrioid carcinoma of the uterus; An Immunohistochemical Study. Ann Cytol Pathol. 2018;2(1):001–8. 
[33] de Freitas D, Aguiar FN, Anton C, Bacchi CE, Carvalho JP, Carvalho FM. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion. PLoS One. 2018;13(12):e0209294. 
[34] Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018;119(4):480–6. 
[35] Corrado G, Laquintana V, Loria R, Carosi M, de Salvo L, Sperduti I, et al. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res. 2018;37:1–10. 
[36] Vizza E, Mancini E, Laquintana V, Loria R, Carosi M, Baiocco E, et al. The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker. Surg Oncol. 2019;28:151–7. 
[37] Asano H, Hatanaka KC, Matsuoka R, Dong P, Mitamura T, Konno Y, et al. L1CAM predicts adverse outcomes in patients with endometrial cancer undergoing full lymphadenectomy and adjuvant chemotherapy. Ann Surg Oncol. 2020;27:2159–68. 
[38] Elyamany G, Shams Eldin M, Abd Elhamid A, El-Sayed M. Prognostic significance of L1 cell adhesion molecule (L1CAM) expression in endometrial carcinoma. J Egypt Natl Canc Inst. 2020;32(1):38. 
[39] Chalia J, Hussein M, Farooqui M, Mattson J, Mullany SA, Klein ME, et al. Concurrent immunohistochemical testing of L1CAM and MMR proteins adds value in risk stratification of endometrial cancer: a proof of concept. Eur J Gynaecol Oncol. 2021;42(5). 
[40] Guo M, Gong H, Nie D, Li Z. High L1CAM expression predicts poor prognosis of patients with endometrial cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(13):e25330. 


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications